Red Tree Venture Capital and Canaan Partners led a $67 Series A round in Rondo Therapeutics.

Red Tree Venture Capital, an investment company, and Canaan Partners, an early-stage venture capital firm, led a $67 Series A round in Rondo Therapeutics, a biopharmaceutical company, with participation from Johnson & Johnson Innovation, Novo Holdings and SV Health Investors. "We are thrilled with the strong investment syndicate we have brought together. Each investment partner brings a unique perspective along with deep experience in therapeutics and a true understanding of what it takes to develop first- and best-in-class drugs. As repeat entrepreneurs, we know the value of having highly engaged investors that share our vision for building Rondo," Shelley Force Aldred, Rondo Therapeutics Co-Founder and Chief Executive Officer.